| Literature DB >> 22028955 |
K E Kramoh1, E Aké-Traboulsi, C Konin, Y N'goran, I Coulibaly, A Adoubi, J Koffi, J B Anzouan-Kacou, M Guikahue.
Abstract
Background. Since the treatment of hypertension is beneficial for the elderly, we have undertaken this study that aims to evaluate the management of hypertension in elderly patient in Côte d'Ivoire. Methods. A retrospective study was conducted among 854 hypertensive elderly patients of Abidjan Cardiology Institute who were followed for a minimum of one year, between January 2000 and December 2009. Results. The patients mean age was 73.1 ± 5.3 years, and 59% were women. At the first presentation, it was mostly systolic-diastolic hypertension (51.8%) and isolated systolic hypertension (38.5%). Mean blood pressure was 169.4 ± 28.4 mmHg for systolic, 95.3 ± 15.7 mmHg for diastolic, and 74.1 ± 22.8 mmHg for pulse pressure. Pulse pressure was ≥60 mmHg in 80.4%. According to the European Guidelines stratification of the cardiovascular risk-excess attributable to high blood pressure, 82.1% of the sample had a very high added risk. The pharmacological therapy was prescribed in 93.5%. More than 66% of patients were receiving ≥2 antihypertensive drugs including fixed-dose combination drugs. The most common agents used were diuretics (63.5%) followed by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in 61.3%. The most common agents used for monotherapy were calcium antagonists. When ≥2 drugs were used, diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were the most common. Blood pressure control was achieved in 42.6%. Conclusion. The control of elderly hypertension can be effective in Sub-Saharan Africa. He required at least two antihypertensive drugs to meet the recommended blood pressure target.Entities:
Year: 2011 PMID: 22028955 PMCID: PMC3199044 DOI: 10.1155/2012/651634
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Population distribution according to the classification of blood pressure, the other cardiovascular risk factor, and target organ damage at first presentation.
| Clinical data | % |
|---|---|
| Classification of blood pressure | |
|
| |
| Controlled blood pressure | 9.2 |
| Systolic and diastolic hypertension (51.8%) | |
| Grade1 hypertension | 4.8 |
| Grade 2 hypertension | 14.7 |
| Grade 3 hypertension | 32.3 |
| Isolated systolic hypertension (38.5%) | |
| Grade1 hypertension | 16.8 |
| Grade 2 hypertension | 12.7 |
| Grade 3 hypertension | 9 |
| Isolated diastolic hypertension | 0.5 |
|
| |
| Other cardiovascular risk factor | |
|
| |
| Dyslipidemia | 56% |
| Diabetes | 18.6 |
| Smoking | 23.7 |
| Obesity | 33.8 |
| Abnormal pulse pressure | 80.4 |
|
| |
| Organ damage | |
|
| |
| No organ damage | 36.3 |
| One organ damage | |
| Cardiovascular | 37.9 |
| Neurological | 9.8 |
| Renal | 2.7 |
| More than one organ damage | |
| Cardiovascular + renal | 8.5 |
| Cardiovascular + neurological | 3.1 |
| Renal + neurological | 0.6 |
| Cardiovascular + neurological + renal | 1.1 |
Type of drugs used.
| Type of drug |
|
|---|---|
|
| |
| Calcium antagonists | 36.3 |
| RAS blockers | 32 |
| Diuretics | 16 |
|
| 10.7 |
| CAS | 5 |
|
| |
|
| |
| RAS blockers + Diuretics | 69.8 |
|
| 8.5 |
|
| 7.4 |
| Diuretics + Calcium antagonist | 5.5 |
| RAS Blockers + Calcium antagonists | 3.5 |
| RAS Blockers + | 3.5 |
| CAS + (diuretics or RAS blockers or calcium antagonist or | 1.8 |
|
| |
|
| |
| RAS blockers + Diuretics + Calcium antagonists | 51.7 |
| RAS blockers + Diuretics + | 18.4 |
| Diuretics + | 17.2 |
| RAS blockers + | 2.3 |
| Other using CAS | 10.4 |
|
| |
|
| |
| RAS blockers + Diuretics + Calcium antagonists + | 58.8 |
| RAS blockers + Diuretics + Calcium antagonists+ CAS | 35.3 |
| RAS blockers + Diuretics + | 5.9 |
RAS blockers: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, CAS: Centrally acting sympatholytics.
Change in blood pressure for all patients.
| Blood pressure (mmHg) | First presentation | Last presentation |
|
|---|---|---|---|
| SBP | 169.4 ± 28.4 | 153.5 ± 26.1 | <0.001 |
| DBP | 95.3 ± 15.7 | 87.1 ± 14.3 | <0.001 |
| PP | 74.1 ± 22.7 | 66.5 ± 19.9 | <0.001 |
Figure 1Changes in blood pressure during followup.
Change in blood pressure by gender.
| Blood pressure (mmHg) | Male | Female |
| |
|---|---|---|---|---|
| SBP | 171 ± 28.6 | 168.3 ± 28.3 | 0.28 | |
| First presentation | DBP | 95 ± 16.3 | 95.4 ± 15.3 | 0.39 |
| PP | 76 ± 23.3 | 72.9 ± 22.3 | 0.24 | |
|
| ||||
| SBP | 155.4 ± 27.1 | 152.2 ± 25.4 | 0.88 | |
| Last presentation | DBP | 87.9 ± 14.9 | 86.5 ± 13.9 | 0.89 |
| PP | 67.4 ± 19.5 | 65.7 ± 20.2 | 0.03 | |
|
| ||||
| Control rate | 39.2 | 45.0 | 0.88 | |
DBP: Diastolic blood pressure, PP: Pulse pressure, SBP: Systolic blood pressure.